edratide

Peptideexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jul 1, 2005 (NCT00203151)

Timeline

2000s

Jan 1, 2005
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Lupus Erythematosus, Systemic · Phase 2

Mechanism of action

dsDNA antibodiesINHIBITOR
dsDNA antibodies inhibitor

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)NCC(=O)O)[C@@H](C)CC)[C@@H](C)CC

Mol. weight: 2307.6 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL2107743 ↗

Also known as

edratide
edratide
edratide
edratide
hcdr1 peptide
tv-4710

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00203151	Phase 2	Jul 1, 2005	Teva

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Teva	For profit	1	1	1	2005

1 organizations

Page 1 / 1